10x Genomics Inc (NASDAQ:TXG) currently has a daily average trading volume of 1.89M but it saw 1966345 shares traded in last market. With a market cap of 2.38B USD, the company’s current market price of $19.92 came rising about 5.01 while comparing to the previous closing price of $18.97. In past 52 weeks, the stock remained buoying in the range of price level as high as $63.57 and as low as $15.28.
Taking a look at 20-day trading activity of 10x Genomics Inc (TXG) gives us an average price of $18.38, while its current price level is -68.66% below from 52-week high level whereas it is 30.37% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $20.66 while that of 200 days or SMA-200 reads an average of $36.01. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.71% during that period while stretching the period over a month that decreases to 6.57%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 53.49 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Jefferies which upgraded the stock as “Buy” in its note to investors issued on July 22, 2024, recommending a price target of $24 for it. JP Morgan downgraded its recommendation for the stock as a “Neutral” from “Overweight” on July 18, 2024 while assigning a price target range of $40-$20. Deutsche Bank issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $55 and $25.
Over the week, TXG’s stock price is moving 20.29% up while it is 1.68% when we observe its performance for the past one month. Year-to-date it is -64.40% down and over the past year, the stock is showing a downside performance of -67.27%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.53 beaten by the consensus estimate of -0.4 for the same. In next quarter, company is expected to be making quarterly sales of $171.93M as analysts are expecting the sales for current fiscal year at $663.06M and seeing the company making $750.45M in sales next year. Moreover, analysts are in estimates of $150.09M for current-quarter revenue.
Currently, 10x Genomics Inc’s total number of outstanding shares is 105.04M. Company’s return on investment (ROI) stands at -33.04% and return on equity (ROE) at -34.75%. Stock’s beta reads 1.84. Stock has a price to book (P/B) ratio of 3.32 while price to sale or P/S ratio amounts to 3.81. Its return on asset (ROA) is -27.29% on average.
